Editor's Choice FORM

Drug shortage help on horizon
Drug shortage help on horizonWhile hospitals continue to face IV saline shortages after two hurricanes significantly damaged infrastructure in Puerto Rico, the situation should improve early this year.
Top 5 pipeline drugs for 2018
Top 5 pipeline drugs for 2018New blockbuster drugs to treat various conditions are expected to be among the top drugs to hit the marketplace in 2018. Here are 5 of the top new drugs in the pipeline for 2018, according to analysts.
New treatment for advanced kidney cancer approved
New treatment for advanced kidney cancer approvedFDA expanded the indication on cabozantinib (Cabometyx, Exelixis) to treat patients with advanced renal cell carcinoma (RCC).
FDA okays short-acting follow-on insulin for diabetes
FDA okays short-acting follow-on insulin for diabetesFDA okays the first short-acting insulin approved as a “follow-on” product.
New cancer biosimilar could net major sales
New cancer biosimilar could net major salesA new biosimilar to the cancer drug Herceptin, which raked in $2.5 billion in US sales last year, is expected to produce blockbuster sales in the US.
FDA approves breakthrough cancer gene test
FDA approves breakthrough cancer gene testFDA approved a new cancer biomarker test that can detect genetic mutations in 324 genes and 2 genomic signatures in tumors.
Four oncology treatment advances to watch
Four oncology treatment advances to watchExperts say a cancer care revolution is here. Here’s a closer look at some advancements in cancer treatments to watch.
FDA issues warning over marijuana products claiming cancer cure
FDA issues warning over marijuana products claiming cancer cureFDA warned 4 companies, which are claiming that their products containing cannabidiol, can treat or cure cancer.
Cholesterol drug misbranded, company pleads guilty
Cholesterol drug misbranded, company pleads guiltyPharma maker pleads guilty that one of its major drugs was misbranded in a federal court case brought by FDA and the US Department of Justice.
FDA alters stance on opioid addiction drugs
FDA alters stance on opioid addiction drugsFDA is advising that these 2 opioid addiction medications should not be withheld from patients taking benzodiazepines or other drugs that depress the central nervous system.